Orchestra BioMed price to book ratio OBIO

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 17.4×
6-year median: 5.2×
Against its 6-year history: 73rd; percentile: 0 is its lowest day, 100 its highest
6-year range: 1.8× to 58.8×
Peer median: 2.6×

Orchestra BioMed's price to book ratio is 17.4× as of Oct 23, 2026.

That is above its 6-year median of 5.2×, higher than on 73% of days in the last 6 years.

Over that time it ranged from 1.8× in Oct 2023 to 58.8× in Feb 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 2.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.4×	4.3×	19.0×
2025	5.6×	3.1×	7.5×
2024	3.6×	2.3×	5.7×
2023	4.1×	1.8×	6.1×
2022	n/m a value too high to mean anything
2021	40.3×	40.0×	58.8×
2020	52.4×	44.6×	52.4×

Against its peers

Companies in Medical - Instruments & Supplies nearest Orchestra BioMed's size, closest first, today.

Company	Price to book ratio
OBIOOrchestra BioMed	17.4×
EMBCEmbecta	n/m
INFUInfuSystem	4.7×
UTMDUtah Medical Products	1.9×
TCMDTactile Systems Technology	2.4×
PDEXPro DEX	4.2×
MDXGMimedx	2.6×
MOVMovado	1.4×
IRMDIradimed	10.8×
STAAStaar Surgical	3.1×
KEQUKewaunee Scientific	1.3×
Peer median	2.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Orchestra BioMed

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.